肥胖儿童阻塞性睡眠呼吸暂停的危险因素:系统性审查和元分析
Catharina Tao1, Mary Fortune2, Emma A Webb3
1Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, United Kingdom.
Paediatric respiratory reviews
|January 9, 2026
概括
肥胖儿童的阻塞性睡眠呼吸暂停 (OSA) 是多因素的,与更高的BMI,部/腰围和腺突增大有关. 早期识别这些风险因素对于有效干预至关重要.
科学领域:
- 儿科肺病学 儿科肺病学
- 睡眠医学 睡眠医学
- 肥胖问题研究研究
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 在肥胖儿童中很常见,导致严重的长期健康问题.
- 在这个人群中确定OSA的风险因素对于早期诊断和管理至关重要.
研究的目的:
- 系统地审查和对0-18岁超重和肥胖儿童阻塞性睡眠呼吸暂停 (OSA) 的风险因素进行元分析.
- 综合各种因素与儿童肥胖症中OSA患病率之间的关联的证据.
主要方法:
- 47项研究的系统审查和元分析.
- 在PubMed和Embase数据库中进行了搜索.
- 应用随机效应模型来分析风险因素,包括肥胖,腺突增大,性别,种族和呼吸道神经肌肉度.
主要成果:
- 与没有OSA的肥胖儿童相比,患有OSA的儿童表现出更高的BMIz分数,子周长和腰围.
- 腺囊缩和男性性别显著与增加OSA的几率有关.
- 初步证据表明,气道神经肌肉调和非高加索族裔是潜在的风险因素,需要进一步调查.
结论:
- 肥胖儿童的阻塞性睡眠呼吸暂停是一种复杂的疾病,受多种因素的影响.
- 考虑各种风险因素的综合评估可以提高查准确度.
- 针对这种高风险儿科患者群体的有针对性的干预措施可以通过多因素方法来指导.
相关概念视频
Sleep Apnea
469
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
469
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
Drug Dosing: Obese Patients
217
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
217
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
Other Pulmonary Disorders
1.5K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.5K


